1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
biote Corp.

biote Corp.

BTMD
biote Corp.US flagNASDAQ Global Market
2.46
USD
+0.03
- -
108.50MMarket Cap
biote Corp.
BTMD
(NASDAQ Global Market)

Recent

price

2.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
14.52
15.39
18.4
20.47
7.21
5.75
6.14
6.06
Revenue per Share
2.81
3.85
4.31
-0.12
0.13
0.09
0.86
0.5
Basic EPS, GAAP
3.13
3.3
3.95
-1.18
1.03
1.13
0.96
0.93
Free Cash Flow per Basic Share
7.48
1.76
1.51
1.6
0.34
0.14
0.06
0.05
Dividend per Share
- -
-2.25
0.55
-5.52
-1.14
-2.93
-1.58
-1.48
Book Value per Share
- -
-2.6
-0.06
-7.86
-1.61
-3.43
-2.08
-2.02
Tangible Book Value per Share
8
8
8
8
26
34
31
31
Basic Weighted Avg Shares
110
117
139
165
185
197
192
188
Sales/Revenue/Turnover
21.39
27.26
24.79
-36.81
15.46
16.03
18.5
15.43
Operating Margin (%)
1
1
1
2
3
4
4
4
Depreciation Expense
21
29
33
-1
3
3
27
16
Net Income, GAAP
0.43
0.64
0.87
22.66
- -
95.47
15.93
21.45
Effective Tax Rate (%)
19.36
25.02
23.4
-0.59
1.79
1.6
14.07
8.29
Profit Margin (%)
- -
16
30
82
100
17
10
8
Working Capital
- -
37
32
114
108
104
103
102
LT Debt
- -
-17
4
-58
-37
-102
-50
-48
Total Equity
- -
261.79
106.76
-91.82
- -
3.4
94.64
52.78
Return on Invested Capital (%)
- -
249.55
102.62
-0.26
- -
14.61
76.57
41
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7
7
7
LT Borrowings
97
101
99
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
30
Market Capitalization
94
81
42

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
57
55
36
Cash, Cash Equivalents & STI
28
24
5
Accounts Receivable, Net
8
7
7
Inventories
16
19
20
Total Current Liabilities
56
45
28
Payables & Accruals
9
11
14
ST Debt
7
7
7
Deferred Revenue
3
3
3

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-309.04%
-50.69%
Free Cash Flow
- -
-93.53%
-22.25%
Net Income, GAAP
- -
43.71%
756.67%
Sales/Revenue/Turnover
- -
10.83%
-2.52%
Total Cash Common Dividend
- -
-28.59%
-63.6%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
47
49
51
50
197
2025
49
49
48
46
192
2026
45
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.21
0.34
0.12
0.09
2025
0.44
0.1
0.26
0.06
0.86
2026
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
0.01
- -
0.14
2025
0.02
0.03
- -
- -
0.06
2026
0.01
- -
- -
- -
- -
Similar Companies
Artemis Medicare Services Limited (ARTEMISMED.BO)
Orpea S.A. (ORP.PA)
Japan Hospice Holdings Inc. (7061.T)
Fresenius Medical Care AG & Co. KGaA (FMS)
Universal Health Services, Inc. (0LJL.L)
Orpea S.A. (ORPEF)
Business
biote Corp. operates a growth-focused medical practice-building enterprise within the expansive hormone optimization and therapeutic wellness industry. The company furnishes a comprehensive, integrated platform, known as the Biote Method, empowering its certified medical providers to develop and manage programs designed to balance patient hormone, vitamin, and mineral levels. This offering includes specialized education, training, and certification in bioidentical hormone therapies, alongside advanced practice and inventory management software, and digital marketing tools. biote also markets its proprietary line of dietary supplements and sterile kits for hormone pellet insertions. Serving a broad population of American men and women experiencing hormonal imbalances, the company enhances its supply chain efficiency through vertical integration, notably with the 2024 acquisition of Asteria Health. Founded in 2012, biote Corp. is based in Irving, Texas.

Company News

MCPAPIChat

  • businesswire.com

    Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

  • gurufocus.com

    Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

  • businesswire.com

    Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

  • seekingalpha.com

    biote Corp. (BTMD) Q1 2026 Earnings Call Transcript

  • zacks.com

    biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates

  • businesswire.com

    Biote Reports First Quarter 2026 Financial Results

  • businesswire.com

    Biote Schedules First Quarter 2026 Financial Results Release and Conference Call

  • seekingalpha.com

    biote Corp. (BTMD) Q4 2025 Earnings Call Transcript

  • zacks.com

    biote Corp. (BTMD) Q4 Earnings and Revenues Top Estimates

  • businesswire.com

    Biote Reports Fourth Quarter and Full Year 2025 Financial Results

  • businesswire.com

    Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call

  • defenseworld.net

    Head to Head Comparison: Agilent Technologies (NYSE:A) vs. biote (NASDAQ:BTMD)

  • defenseworld.net

    biote Corp. $BTMD Stock Position Lessened by Bandera Partners LLC

  • seekingalpha.com

    biote Corp. (BTMD) Q3 2025 Earnings Call Transcript

  • zacks.com

    biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates

  • businesswire.com

    Biote Reports Third Quarter 2025 Financial Results

  • businesswire.com

    Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call

  • seekingalpha.com

    Restructuring At Biote Will Drive Greater Growth And Profitability

  • seekingalpha.com

    biote Corp. (BTMD) Q2 2025 Earnings Call Transcript

  • zacks.com

    biote Corp. (BTMD) Tops Q2 Earnings Estimates